Event driven snapshot of BioMarin Pharmaceutical

BioMarin Pharmaceutical (BMRN) is back on investor radars after recent share price moves, with the stock up about 8% over the past month and roughly 10% over the past 3 months.

While the recent 30 day share price return of about 8% and 90 day gain of roughly 10% suggest momentum is building again, the 1 year total shareholder return of about a 13% decline and a roughly 39% decline over three years show a tougher longer term picture.

If this kind of rebound in a specialist biotech is on your radar, it could be a good moment to see what else is moving and check out 27 healthcare AI stocks as a starting list of ideas.

With BioMarin reporting US$3.2b in revenue and US$348.9m in net income, plus a market price of US$61.73 that implies a sizeable intrinsic discount, the key question is whether this is a genuine opening or if the market already reflects future growth.

Most Popular Narrative: 30.4% Undervalued

The most followed narrative values BioMarin at about $88.65 per share compared with the last close of $61.73, framing the current move as potentially driven by a valuation gap.

Recent Street research on BioMarin Pharmaceutical reflects a mix of optimism and caution, with analysts updating their views on the company’s execution, growth profile, and valuation assumptions. For you as an investor, the key is understanding where they see potential upside and where they see risks that could justify more conservative fair value estimates.

Curious what sits behind that gap between price and fair value? The narrative leans heavily on faster earnings growth, firmer revenue expectations, and a richer future earnings multiple. The exact mix of those inputs matters a lot for the $88.65 figure.

Result: Fair Value of $88.65 (UNDERVALUED)

However, this story can shift quickly if competition dents VOXZOGO’s growth, or if higher R&D and commercial costs squeeze margins more than analysts currently model.

Another Angle on Valuation

The narrative models BioMarin as 30.4% undervalued, but the current P/E of 34x versus the US Biotechs average of 21.7x and a fair ratio of 26.8x tells a different story. That premium suggests valuation risk if sentiment cools, so which signal should investors consider more closely?

Next Steps

If this mix of optimism and concern resonates with you, take a moment to review the numbers yourself and move quickly to shape your own view, then check our breakdown of 2 key rewards and 1 important warning sign to see how the trade off looks in full.

Looking for more investment ideas?

If BioMarin has you thinking more broadly about where to put your money to work, do not stop at one name. Widen your search before the next move.

• Spot potential bargains early by scanning our list of screener containing 24 high quality undiscovered gems that combine strong fundamentals with limited market attention.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Target quality at a reasonable entry point with 46 high quality undervalued stocks filtered for solid businesses trading below their assessed worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.